PHARMACOLOGY 1
🇬🇧
In Inglés
In Inglés
Practique preguntas conocidas
Manténgase al día con sus preguntas pendientes
Completa 5 preguntas para habilitar la práctica
Exámenes
Examen: pon a prueba tus habilidades
Pon a prueba tus habilidades en el modo de examen
Aprenda nuevas preguntas
Popular en este curso
Aprende con fichas
Modos dinámicos
InteligenteMezcla inteligente de todos los modos
PersonalizadoUtilice la configuración para ponderar los modos dinámicos
Modo manual [beta]
Seleccione sus propios tipos de preguntas y respuestas
Otros modos disponibles
Completa la oración
Escuchar y deletrearOrtografía: escribe lo que escuchas
elección múltipleModo de elección múltiple
Expresión oralResponde con voz
Expresión oral y comprensión auditivaPractica la pronunciación
EscrituraModo de solo escritura
PHARMACOLOGY 1 - Marcador
También te puede interesar
PHARMACOLOGY 1 - Detalles
Niveles:
Preguntas:
870 preguntas
| 🇬🇧 | 🇬🇧 |
| The science of substances used to prevent, diagnose and treat disease. | Medical Pharmacology |
| The science of drug preparation and the medical use of drugs -- the precursor of pharmacology | Materia Medica |
| Two General Principles (PHARMACOLOGY) | 1 All substances can under circumstances be toxic, and the chemicals in botanicals are no different from chemicals in manufactured drugs except for the proportion of impurities 2 All dietary supplements and all therapies promoted as health-enhancing should meet the same standards of efficacy and safety as conventional drugs and medical therapies |
| The study of the GENETIC VARIATIONS that cause differences in drug response among individuals or populations. | Pharmacogenomics (also called Pharmacogenetics) |
| The use of drugs to prevent and treat disease | Pharmacotherapeutics |
| Brand name/ Proprietary name Selected by the drug company selling the product Protected by copyright | Trade Name |
| Family Drugs that share similar characteristics Ex: Beta-adrenergic blockers | Pharmacologic Class |
| Groups drugs by therapeutic use Ex: Antihypertensives | Therapeutic Class |
| POWER PLANT: | 1 Alkaloids 2 Glycosides 3 Gums 4 Resins 5 Oils |
| Animal Magnetism Drugs obtained from animal sources | 1 hormones such as insulin 2 oils and fats (usually fixed) - cod liver oil 3 enzymes - pancreatin and pepsin 4 vaccines |
| Mineral Springs: __ | • Iron • Iodine • Epsom salt |
| Drugs produced in the laboratory | Down to DNA |
| Routes of Administration | • buccal, sublingual, translingual • gastric • intradermal • intramuscular • intravenous • oral • rectal and vaginal • respiratory • subcutaneous • topical |
| 1 activator -has affinity to the receptor and intrinsic activity 2 Inhibitor -has affinity only | 1 AGONIST 2 ANTAGONIST |
| Inhibitor has affinity only | ANTAGONIST |
| May interact directly with other drugs | Chemical Antagonists |
| The Physical Nature of Drugs | • Solid - Aspirin, Atropine • Liquid - Nicotine, Ethanol • Gaseous - Nitrous Oxide |
| Drug Size, SMALLEST and LARGEST | 1 Smallest -- Lithium ion (MW 7) 2 Largest -- Alteplase (MW 59,050) 3 Most drugs -- MW 100-1000 |
| Three major types of bonds | 1 covalent, 2 electrostatic and 3 hydrophobic |
| Implies the ability to predict the appropriate molecular structure of a drug on the basis of information about its biologic receptor | Rational Drug Design |
| Must undergo extensive animal studies | IND - Investigational New Drug |
| 1 actions of drug on the body 2 actions of the body on the drug | 1 Pharmacodynamics 2 Pharmacokinetics |
| Involves trials with people who have the disease for which the drug is thought to be effective. | Phase II |
| Exceptions to the Rule | 1 Public health threat of disease like AIDS, COVID-19 2 Sponsors of drugs that reach phase II or III clinical trials can apply for FDA approval of treatment IND status |
| 1 actions of drug on the body 2 actions of the body on the drug | 1 Pharmacodynamics 2 Pharmacokinetics |
| LADMERS | • Liberation of an active ingredient from the dosage form • Absorption into systemic circulation • Distribution • Metabolism in the body • Excretion of the drug from the body • Response |
| • directly proportional to the concentrations, surface area and permeability coefficient • inversely proportional to the thickness of the membrane | Fick's Law of Diffusion |
| Reverse of endocytosis | Exocytosis |
| Factors influencing absorption | 1 Effect of pH on drug absorption 2 Blood flow to the absorption site 3 Total surface area available for absorption 4 Contact time at the absorption surface |
| Absorbs nutrients in the small intestine | Microvilli |
| Responsible for transporting various molecules, including drugs, across cell membranes - "pumps" drugs out of the cells - associated with multi-drug resistance | Expression of P-glycoprotein |
| Bioavailability is usually measured using __ | Area Under the Curve (AUC) |
| 1) 100% Bioavailability, most rapid onset 2) 5 to <100 Bioavailability, most convenient; may have significant First Pass Effect | 1 Intravenous 2 Oral |
| Factors Influencing Bioavailability: when a drug is absorbed from the GI tract, it enters the PORTAL CIRCULATION before entering the systemic circulation | First-pass Hepatic Metabolism |
| Factors Influencing Bioavailability | 1 First-pass Hepatic Metabolism 2 Solubility of the drug 3 Chemical instability 4 Nature of the drug formulation |
| Show comparable bioavailability and similar times to achieve peak blood concentrations | BIOEQUIVALENCE |
| Pharmaceutically equivalent with similar chemical and safety profiles | THERAPEUTIC EQUIVALENCE |
| If the drugs have the same dosage form, contain the same active ingredient, and use the same route of administration | Pharmaceutical Equivalence |
| The process by which a drug reversibly leaves the bloodstream and enters the instertitium (extracellular fluid) and the tissues | DRUG DISTRIBUTION |
| The process by which a drug reversibly leaves the bloodstream and enters the instertitium (extracellular fluid) and the tissues. | DRUG DISTRIBUTION |
| What are the Special Barriers to Distribution? | 1 Placental (most small molecular weight drugs cross the placental barrier; fetal blood levels are usually lower than maternal) 2 Blood-brain (permeable only to lipid-soluble drugs or those of very low molecular weight) |
| • Concentration of drug at the receptor site • Commonly measured in the blood (Exception for topical agents) | EFFECTIVE DRUG CONCENTRATION |
| Plasma concentration is a function of | – the rate of input of the drug (by absorption) into the plasma – the rate of distribution – and the rate of elimination |
| Pharmacokinetics TWO BASIC PARAMETERS | 1 CLEARANCE 2 VOLUME OF DISTRIBUTION |
| The measure of the apparent space in the body available to contain the drug. | VOLUME OF DISTRIBUTION |
| The ratio of the amount of drug in the body to the drug concentration in the plasma or blood | Volume of distribution -Can be affected by liver and kidney disease |
| METABOLISM OF DRUGS Three major routes: | – Hepatic metabolism – Biliary metabolism – Urinary metabolism |
| Metabolism (Biotransformation) PHASES | 1) Phase I (Functionalization) – Redox Reactions and hydrolysis. 2) Phase II (Conjugation) – Attacks certain drugs with existing functional groups and attaches conjugate molecules |
| Metabolism (Biotransformation) May be affected by | • Drug Interactions due to inducers, inhibitors, and substrates • Genetic factors • Disease states DRUG WITH INDUCER - FASTER DRUGS WITH INHIBITOR - SLOWER |
| EXCRETION; Renal elimination of drugs: | – Glomerular filtration – Proximal tubular secretion – Distal tubular reabsorption |
| Excretion process | 1 Glomerular filtration of water and unbound drugs and metabolites 2 Active tubular secretion of acidic and basic drugs and metabolites 3 Active reabsorption of acidic and basic endogenous compounds and passive reabsorption of lipophilic drugs 4 Urinary excretion of drugs and metabolites that are filtered and or actively secreted and not reabsorbed |
| Describes the actions of a drug on the body and the influence of drug concentrations on the magnitude of the response | PHARMACODYNAMICS |
| • Their ligands are presently unknown • May prove useful targets for the development of new drugs. | ORPHAN RECEPTORS |
| • MEDIATE the actions of endogenous chemical signals such as neurotransmitters, autacoids and hormones. | REGULATORY PROTEINS |
| Membrane receptor for digitalis glycosides a TRANSPORT PROTEIN | Na+/K+ ATPase Pump |
| Ionotropic receptors associated with ligand-gated ion channels Features: LOCATION = __ EFFECT = __ | CLASS 1 LOCATION: Cell membrane EFFECT: millisecond |
| Controls Na+ channels (Ligand-gated) -- inhibited by curare and derivatives, ganglionic blockers | Nicotinic Receptor (CLASS 1) |
| Controls Cl- channels | GABAA-receptor complex (CLASS 1) |
| Metabotropic 7 transmembrane-spanning G-protein-linked Features: LOCATION = __ EFFECT= __ | Class II LOCATION: Cell membrane EFFECT: Seconds |
| G-proteins: __ | 1) Gs 2) Gi 3) Gq |
| Activates adenylyl cyclase which produces the second messenger cyclic adenosine monophosphate (cAMP) | Gs |
| Enzyme-linked receptors • Features: EFFECT = __; possesses tyrosine kinase activity as part of their structure | Class III EFFECT: minutes to hours |
| CLASS III example | • Epidermal growth factor • Atrial natriuretic peptide • Insulin |